| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/30-1/150 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/5000-1/10000 | Human,Mouse,Rat |
| Aliases | INA5; INFA5; leIF G; IFN-alphaG; IFN-alpha-5 |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Synthetic peptide of human IFNA5 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于IFNA5抗体的3篇文献示例(注：以下为模拟内容，实际文献需通过数据库检索确认)：
1. **"Development of a monoclonal antibody specific for human interferon-alpha 5 (IFNA5)"**
- 作者：Smith J, et al.
- 摘要：该研究报道了一种新型抗人IFNA5单克隆抗体的开发，验证了其在ELISA和Western blot中的特异性，并证明其可用于检测血清和细胞培养液中的IFNA5蛋白表达。
2. **"IFNA5 antibody-mediated neutralization suppresses viral replication in vitro"**
- 作者：Li X, et al.
- 摘要：通过体外实验证明，靶向IFNA5的中和抗体可阻断其与受体的结合，显著抑制IFNA5介导的抗病毒活性，为研究干扰素信号通路提供了工具。
3. **"Elevated IFNA5 autoantibodies in systemic lupus erythematosus patients"**
- 作者：Garcia R, et al.
- 摘要：研究发现系统性红斑狼疮(SLE)患者血清中IFNA5自身抗体水平升高，提示其可能参与自身免疫疾病的病理过程，或作为潜在生物标志物。
建议通过PubMed或Google Scholar以"IFNA5 antibody"为关键词筛选近5年文献，优先选择《Journal of Immunology》《Frontiers in Immunology》等专业期刊的研究。
Interferon alpha-5 (IFNA5) is a member of the type I interferon family, which plays a critical role in innate immunity against viral infections and tumor surveillance. As part of the IFN-α subgroup, IFNA5 shares structural homology with other alpha interferons but exhibits distinct receptor-binding affinities and biological activities due to sequence variations. It signals through the IFNAR1/IFNAR2 receptor complex, activating JAK-STAT pathways to induce antiviral proteins and modulate immune cell functions.
IFNA5 antibodies are tools used to detect and quantify IFNA5 in research settings, particularly in studies investigating interferon signaling, viral pathogenesis, autoimmune disorders, and cancer immunotherapy. These antibodies enable the visualization of IFNA5 expression in tissues (via immunohistochemistry), measure its secretion in biofluids (via ELISA), or assess its interaction with receptors (via immunoprecipitation). Commercially available IFNA5 antibodies are typically validated for specificity using knockout controls or recombinant proteins.
Research on IFNA5 has gained attention due to its potential therapeutic applications. For example, dysregulated IFNA5 expression is linked to autoimmune diseases like lupus, while its antitumor properties are explored in oncotherapy. However, functional redundancy among IFN-α subtypes and cross-reactivity challenges in antibody development require careful experimental design. Recent studies also investigate IFNA5's role in COVID-19 cytokine responses, highlighting its broader relevance in infectious disease contexts.
×
